Table 1.
Baseline clinical and inflammatory characteristics for the participants included in the gene expression substudy
| COPD + Asthma | COPD | Asthma | P-valuea | |
|---|---|---|---|---|
| n (%) | 95 | 60 | 35 | |
| Age, mean (SD) | 65 (12) | 68 (10) | 60 (15) | 0.004 |
| Gender, n, male/female | 39/56 | 25/35 | 14/21 | 0.873 |
| Body mass index, mean (SD) | 29.6 (7.4) | 28.7 (7.1) | 31.2 (7.8) | 0.226 |
| Smoking, n, never/ex/current | 43/46/6 | 22/34/4 | 21/12/2 | 0.076 |
| Smoking pack-years, median (Q1, Q3) | 27 (3, 47) | 28 (3, 44) | 17 (7, 47) | 0.720 |
| Post–β2 FEV1 %predicted, mean (SD) | 69 (20) | 59 (17) | 85 (13) | ,0.001 |
| Post–β2 FVC %predicted, mean (SD) | 84 (17) | 81 (17) | 89 (15) | 0.032 |
| FEV1/FVC %, mean (SD) | 62 (13) | 55 (11) | 74 (7) | ,0.001 |
| Airway hyperresponsiveness or bronchodilator response at visit, n (%) | 48 (51) | 33 (55) | 15 (43) | 0.254 |
| Visual analog scale symptom score, mean (SD) | 18.5 (12.1) | 19.5 (12.7) | 16.8 (11.1) | 0.311 |
| ICS use, n (%) | 81 (85) | 52 (87) | 29 (83) | 0.613 |
| ICS dose, beclomethasone equivalent, µm/day, median (Q1, Q3) | 1,000 (500, 2,000) | 1,000 (500, 2,000) | 1,000 (500, 2,000) | 0.812 |
| Number of exacerbations in the year prior to baseline visit | 1 (0, 2) | 1 (0, 2) | 0 (0, 1) | 0.108 |
| ≥2 exacerbations in the prior year, n (%) | 34 (36) | 26 (43) | 8 (23) | 0.045 |
| ≥2 exacerbations in the following year, n (%) | 30 (33) | 22 (39) | 8 (24) | 0.110 |
| Sputum total cell count, ×106/mL, median (Q1, Q3) | 4.1 (2.6, 8.6) | 4.3 (2.6, 9.7) | 4.0 (2.1, 6.2) | 0.363 |
| Sputum neutrophil%, median (Q1, Q3) | 47.6 (32.3, 71.8) | 59.0 (30.8, 73.9) | 45.5 (34.0, 61.8) | 0.264 |
| Sputum eosinophil%, median (Q1, Q3) | 1.5 (0.5, 3.0) | 1.8 (0.8, 3.0) | 1.3 (0.5, 2.8) | 0.351 |
Note:
a
Comparison between COPD and asthma.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; Q, quartile; SD, standard deviation.